Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Inventory (2020 - 2025)

Historic Inventory for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $96.3 million.

  • Bioventus' Inventory rose 693.2% to $96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.3 million, marking a year-over-year increase of 693.2%. This contributed to the annual value of $92.5 million for FY2024, which is 125.04% up from last year.
  • As of Q3 2025, Bioventus' Inventory stood at $96.3 million, which was up 693.2% from $96.5 million recorded in Q2 2025.
  • Bioventus' Inventory's 5-year high stood at $97.6 million during Q3 2023, with a 5-year trough of $34.0 million in Q3 2021.
  • Over the past 5 years, Bioventus' median Inventory value was $88.0 million (recorded in 2023), while the average stood at $78.7 million.
  • In the last 5 years, Bioventus' Inventory soared by 11184.07% in 2021 and then plummeted by 900.54% in 2024.
  • Over the past 5 years, Bioventus' Inventory (Quarter) stood at $61.7 million in 2021, then soared by 37.41% to $84.8 million in 2022, then increased by 7.75% to $91.3 million in 2023, then rose by 1.25% to $92.5 million in 2024, then grew by 4.11% to $96.3 million in 2025.
  • Its Inventory was $96.3 million in Q3 2025, compared to $96.5 million in Q2 2025 and $94.0 million in Q1 2025.